Pfizer has agreed to buy Global Blood Therapeutics for $5.4 billion, a deal that will give the big drugmaker a foothold in the treatment of sickle-cell disease.
Pfizer Agrees to $5.4 Billion Deal for Global Blood Therapeutics
Wall Street Journal - 8 Aug 2022 15:11
Pfizer has agreed to buy Global Blood Therapeutics for $5.4 billion, a deal that will give the big drugmaker a foothold in the treatment of sickle-cell disease.
Share this Article
Recommended